BlueCrest Capital Management’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

BlueCrest Capital Management’s Portfolio INFI Stock Details INFI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-13,289	Closed	-$28K	–	1915
2018 Q1	$28K	Buy	+13,289	New	+$28.5K	﹤0.01%	1439
2017 Q3	–	Sell	-18,614	Closed	-$29K	–	1141
2017 Q2	$29K	Buy	+18,614	New	+$35.9K	﹤0.01%	877

Other funds holding INFI

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

BlueCrest Capital Management's INFI Position: Q2 2018 in Review

BlueCrest Capital Management sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q2 2018, closing a stake of 13,289 shares — an estimated $28K sold.

BlueCrest Capital Management first reported a position in INFI in Q2 2017 and held it in 2 quarters. The position peaked at $29K in Q2 2017. 64 funds tracked by Wall St. Rank hold INFI as of Q2 2018.

BlueCrest Capital Management reported no remaining Infinity Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
BlueCrest Capital Management sold 13,289 Infinity Pharmaceuticals, Inc. shares in Q2 2018, an estimated $28K.
BlueCrest Capital Management first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2017 and held it in 2 quarters.
BlueCrest Capital Management's Infinity Pharmaceuticals, Inc. position peaked at $29K in Q2 2017.
64 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q2 2018.

Based on BlueCrest Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.